We are live on ! Find out more
GT

Glenmede Trust Portfolio holdings

AUM $20.4B
This Fund
S&P 500
This Quarter Est. Return
+8.99%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$21.9B
AUM Growth
+$21.9B
Cap. Flow
-$417M
Cap. Flow %
-1.9%
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$89.3M
2
KEYS icon
Keysight
KEYS
+$86M
3
NKE icon
Nike
NKE
+$78.3M
4
APH icon
Amphenol
APH
+$76.5M
5
CMCSA icon
Comcast
CMCSA
+$72.3M

Top Sells

Rank Stock Value
1
CE icon
Celanese
CE
+$108M
2
MNST icon
Monster Beverage
MNST
+$97.8M
3
SBUX icon
Starbucks
SBUX
+$79.7M
4
TXN icon
Texas Instruments
TXN
+$67.3M
5
CNC icon
Centene
CNC
+$64.3M

Sector Composition

Rank Sector Weight
1 Technology 18.83%
2 Financials 13.42%
3 Healthcare 13.25%
4 Industrials 9.77%
5 Consumer Discretionary 7.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PRA
1651
DELISTED
ProAssurance
PRA
$23K ﹤0.01%
656
+226
+53% +$8.66K
TEVA icon
1652
Teva Pharmaceuticals
TEVA
$40.6B
$23K ﹤0.01%
2,506
-1,400
-36% -$12.5K
WNC icon
1653
Wabash National
WNC
$530M
$23K ﹤0.01%
1,626
+251
+18% +$3.73K
FMO
1654
DELISTED
Fiduciary/Claymore Energy Infrastructure Fund
FMO
$23K ﹤0.01%
600
CSLT
1655
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$23K ﹤0.01%
17,454
ZAYO
1656
DELISTED
Zayo Group Holdings, Inc.
ZAYO
$23K ﹤0.01%
672
AEIS icon
1657
Advanced Energy
AEIS
$10.3B
$22K ﹤0.01%
313
+148
+90% +$9.21K
C.PRN icon
1658
Citigroup Capital XIII 7.875% Fixed Rate/Floating Rate Trust Preferred Securities
C.PRN
$2.48B
$22K ﹤0.01%
800
FLO icon
1659
Flowers Foods
FLO
$1.56B
$22K ﹤0.01%
1,098
IFGL icon
1660
iShares International Developed Real Estate ETF
IFGL
$82.8M
$22K ﹤0.01%
747
IRDM icon
1661
Iridium Communications
IRDM
$4.78B
$22K ﹤0.01%
928
+259
+39% +$6.21K
NMIH icon
1662
NMI Holdings
NMIH
$3.39B
$22K ﹤0.01%
676
+165
+32% +$5.15K
NPO icon
1663
Enpro
NPO
$6.31B
$22K ﹤0.01%
341
+105
+44% +$6.98K
ADAM
1664
Adamas Trust
ADAM
$783M
$22K ﹤0.01%
913
+215
+31% +$5.33K
PRGO icon
1665
Perrigo
PRGO
$1.46B
$22K ﹤0.01%
438
-170
-28% -$8.89K
PSMT icon
1666
Pricesmart
PSMT
$5.94B
$22K ﹤0.01%
+313
New +$22.5K
RMAX icon
1667
RE/MAX Holdings
RMAX
$198M
$22K ﹤0.01%
578
+68
+13% +$2.44K
SAIA icon
1668
Saia
SAIA
$10.4B
$22K ﹤0.01%
243
-1,616
-87% -$153K
SPXC icon
1669
SPX Corp
SPXC
$9.57B
$22K ﹤0.01%
444
+122
+38% +$5.58K
TNC icon
1670
Tennant Co
TNC
$1.44B
$22K ﹤0.01%
292
+71
+32% +$5.29K
TRI icon
1671
Thomson Reuters
TRI
$46.4B
$22K ﹤0.01%
294
-28
-9% -$2.04K
TRST
1672
Trustco Bank Corp NY
TRST
$966M
$22K ﹤0.01%
527
+343
+186% +$14.7K
QVCGB
1673
DELISTED
QVC Group, Inc. Series B Common Stock
QVCGB
$22K ﹤0.01%
55
SWN
1674
DELISTED
Southwestern Energy Company
SWN
$22K ﹤0.01%
9,604
+1,248
+15% +$2.58K
SPLK
1675
DELISTED
Splunk Inc
SPLK
$22K ﹤0.01%
150
-125
-45% -$16.4K

Similar funds

Glenmede Trust's Q4 2019 Portfolio in Review

As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

  • Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
  • Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
  • Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
  • Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
  • Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
  • Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
  • Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.